JP2024541476A5 - - Google Patents

Info

Publication number
JP2024541476A5
JP2024541476A5 JP2024531027A JP2024531027A JP2024541476A5 JP 2024541476 A5 JP2024541476 A5 JP 2024541476A5 JP 2024531027 A JP2024531027 A JP 2024531027A JP 2024531027 A JP2024531027 A JP 2024531027A JP 2024541476 A5 JP2024541476 A5 JP 2024541476A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050934 external-priority patent/WO2023097024A1/en
Publication of JP2024541476A publication Critical patent/JP2024541476A/ja
Publication of JP2024541476A5 publication Critical patent/JP2024541476A5/ja
Pending legal-status Critical Current

Links

JP2024531027A 2021-11-24 2022-11-23 Ctla-4に対する抗体及びその使用方法 Pending JP2024541476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163282887P 2021-11-24 2021-11-24
US63/282,887 2021-11-24
PCT/US2022/050934 WO2023097024A1 (en) 2021-11-24 2022-11-23 Antibodies against ctla-4 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024541476A JP2024541476A (ja) 2024-11-08
JP2024541476A5 true JP2024541476A5 (https=) 2025-11-19

Family

ID=84901675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531027A Pending JP2024541476A (ja) 2021-11-24 2022-11-23 Ctla-4に対する抗体及びその使用方法

Country Status (7)

Country Link
EP (1) EP4436998A1 (https=)
JP (1) JP2024541476A (https=)
KR (1) KR20240123846A (https=)
CN (1) CN119278213A (https=)
AU (1) AU2022396272A1 (https=)
CA (1) CA3238936A1 (https=)
WO (1) WO2023097024A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4590714A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590715A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CZ302706B6 (cs) * 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN109071667A (zh) 2016-03-08 2018-12-21 马弗里克治疗公司 可诱导性结合蛋白和使用方法
CN120795163A (zh) 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
JP7440724B2 (ja) * 2020-04-13 2024-02-29 ビオシオン インコーポレイテッド Ctla4に結合する抗体及びその使用

Similar Documents

Publication Publication Date Title
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
JP2022541435A5 (https=)
JP2023518134A5 (https=)
JP2022523781A5 (https=)
JP2019513370A5 (https=)
JP2022504822A5 (https=)
JP2022504802A5 (https=)
JP2022525478A5 (https=)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
JP2018533371A5 (https=)
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白;TRAAFFIAA)
IL302278A (en) Combination treatment
JP2020522267A (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
JP2022542559A5 (https=)
IL304898A (en) New anti-CD24 antibodies
JP2024539506A5 (https=)
US20230235064A1 (en) Bispecific immune cell engagers with binding specificity for hla-g and another antigen
JP2021523949A5 (https=)
JP2024504162A5 (https=)
JP2024541476A5 (https=)
IL316226A (en) Anti-ror1 antibody and ror1-targeting engineered cells
JP2024539630A5 (https=)
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof